Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

JD Health International Inc.

京东健康股份有限公司

(A company incorporated in the Cayman Islands with limited liability)

(Stock Codes: 6618 (HKD counter) and 86618 (RMB counter))

INSIDE INFORMATION
UNAUDITED UPDATE ON THE 2026 THIRD QUARTER

This announcement is issued by JD Health International Inc. (the "**Company**" or "**JD Health**", and together with its subsidiaries and consolidated affiliated entities, the "**Group**") pursuant to Rule 13.09 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the "**Listing Rules**") and the Inside Information Provisions (as defined under the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Cap. 571 of the Laws of Hong Kong).

Business Update

JD Health continued to strengthen its pharmaceutical and healthcare supply chain, and provide partners with end-to-end commercialization support. As of September 30, 2026, more than 110 pharmaceutical companies had selected JD Health as a launch partner for new drugs. Over 50 new drugs made their debuts on JD Health platform during the quarter, including Bailemian® (百樂眠®), an innovative drug developed by Yangtze River Pharmaceutical Group; Jinbeixin® (金蓓欣®), a domestically developed innovative gout therapy from GeneScience Pharmaceuticals; and Hengyi® (恆宜®), a new drug from Hengrui Pharma. JD Health also deepened collaboration with partners including LEO Pharma, Everest Medicines and Likang Life Sciences. The Company is exploring innovative service models for AI-enabled patient services in selected medical specialties and end-to-end chronic disease management, with the aim of improving medicine accessibility and patients' medication experience.

During the third quarter of 2026, JD Health continued to expand its instant delivery services coverage and its partner pharmacy network. The Company extended the late-night medicine delivery service to more than 300 cities nationwide, with 24/7 access to online pharmacists. JD Health also upgraded its cold-chain medicine delivery services in multiple cities, providing end-to-end temperature control and real-time monitoring throughout the delivery process for more than 100 types of medicines, further strengthening its omnichannel pharmaceutical fulfillment capabilities.

JD Health continued to improve the online healthcare experience, broadening the use of AI in general health consultations and disease-specific health management. During the third quarter of 2026, its AI agent, "Dr. Da Wei" (大為醫生), served a rapidly growing user base, with average daily interactions increasing by more than fivefold year over year, supporting broader use of online healthcare services. JD Health also partnered with leading medical teams to develop AI solutions for specialized medical fields, including dermatology, mental health, respiratory health, chronic diseases and metabolic disorders. These AI agents provide personalized health guidance and long-term follow-up, helping users access integrated healthcare services across JD Health's ecosystem, spanning consultation, examination, diagnosis and pharmaceutical services.

Unaudited Financial Information

The Company is pleased to announce the unaudited revenue, operating income and profit of the Group for the three months ended September 30, 2026 together with comparative figures for the corresponding period of 2025:

	Three months ended September 30,		Year-over-year change
	2026	2025	
	RMB'000	*RMB'000*	
	(Unaudited)	(Unaudited)	
Revenue	**20,017,199**	17,119,726	16.9%
Operating income[(1)]	**1,195,289**	1,243,290	(3.9%)
Non-IFRS operating income[(2)]	**1,574,607**	1,377,755	14.3%
Profit for the period	**1,557,284**	1,838,503	(15.3%)
Non-IFRS profit for the period[(3)]	**1,930,969**	1,902,237	1.5%

(1) Operating income consists of gross profit deducting fulfillment expenses, selling and marketing expenses, research and development expenses, general and administrative expenses, and impairment losses (including reversals of impairment losses) on financial assets.

(2) We define "non-IFRS operating income" as operating income for the period, excluding share-based payment expenses for the period. We exclude this item because it is non-operating in nature, not indicative of our core operating results and business outlook, and it does not generate any cash outflows.

(3) We define "non-IFRS profit" as profit for the period, excluding share-based payment expenses, fair value changes for financial assets at fair value through profit or loss except for wealth management products, and tax effects on non-IFRS adjustments for the period. We exclude these items because they are either non-operating in nature, or they are not indicative of our core operating results and business outlook, or do not generate any cash outflows.

The above information is based on the board (the "**Board**") of directors (the "**Directors**") of the Company's preliminary review of the internal data currently available and gathered by the Company only and is not intended to be a comprehensive statement of the Group's financial result. The said information and data have not been audited or reviewed by the Company's auditors and may be subject to change and adjustment.

Shareholders of the Company and potential investors are advised to exercise caution when dealing in the shares of the Company.

By order of the Board
JD Health International Inc.
Mr. Dong Cao
Executive Director

Hong Kong, November 17, 2026

As of the date of this announcement, the Board comprises Mr. Dong Cao as the executive Director, Mr. Richard Qiangdong Liu as non-executive Director, and Ms. Ling Li, Dr. Jiyu Zhang, Mr. Xingyao Chen, Mr. Ying Wu and Professor George Lau as independent non-executive Directors.